Literature DB >> 11580308

Dementia in patients undergoing long-term dialysis: aetiology, differential diagnoses, epidemiology and management.

P M Rob1, C Niederstadt, E Reusche.   

Abstract

Dementia in patients undergoing long-term dialysis has not been clearly defined; however, four different entities have been described. Uraemic encephalopathy is a complication of uraemia and responds well to dialysis. Dialysis encephalopathy syndrome, the result of acute intoxication of aluminium caused by the use of an aluminium-containing dialysate, was a common occurrence prior to 1980. However, using modern techniques of water purification, such acute intoxication can now be avoided. Dialysis-associated encephalopathy/dementia (DAE) is always associated with elevated serum aluminium levels. Pathognomonic morphological changes in the brain have been described, but the mechanism for the entry of aluminium into the CNS is incompletely understood. The mechanisms involved in the pathogenesis of the neurotoxicity associated with aluminium are numerous. Although only a very small fraction of ingested aluminium is absorbed, the continuous oral aluminium intake from aluminium-based phosphate binders, and also of dietary or environmental origin, is responsible for aluminium overload in dialysis patients. Age-related dementia, especially vascular dementia, occurs in patients undergoing long-term dialysis as frequently as it does in the general population. The differential diagnoses of dialysis-associated dementias should include investigation for metabolic encephalopathies, heavy metal or trace element intoxications, and distinct structural neurological lesions such as subdural haematoma, normal pressure hydrocephalus, stroke and, particularly, hypertensive encephalopathy and multi-infarct dementia. To prevent DAE, dietary training programmes should aim to achieve the lowest phosphate intake and pharmacological tools should be used to keep serum phosphate levels below 2 mmol/L. To prevent vascular dementia, lifestyle modification should be undertaken, including optimal physical activity and fat intake, nicotine abstinence, and targeting optimal blood glucose, cholesterol and triglyceride levels, and blood pressure, to those outlined in current recommendations.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11580308     DOI: 10.2165/00023210-200115090-00003

Source DB:  PubMed          Journal:  CNS Drugs        ISSN: 1172-7047            Impact factor:   5.749


  61 in total

1.  RenaGel, a nonabsorbed calcium- and aluminum-free phosphate binder, lowers serum phosphorus and parathyroid hormone. The RenaGel Study Group.

Authors:  E A Slatopolsky; S K Burke; M A Dillon
Journal:  Kidney Int       Date:  1999-01       Impact factor: 10.612

2.  Intraneuronal aluminum potentiates iron-induced oxidative stress in cultured rat hippocampal neurons.

Authors:  C X Xie; M P Mattson; M A Lovell; R A Yokel
Journal:  Brain Res       Date:  1996-12-16       Impact factor: 3.252

3.  Increased body aluminum. An independent risk factor in patients undergoing long-term hemodialysis?

Authors:  J A Chazan; S L Blonsky; J G Abuelo; J C Pezzullo
Journal:  Arch Intern Med       Date:  1988-08

4.  [The value of the blood brain barrier in the pathogenesis of neurologic diseases in extraneural metabolism disorders--example of kidney insufficiency].

Authors:  A Prill
Journal:  Nervenarzt       Date:  1970-10       Impact factor: 1.214

5.  Prevalence of dementia and major subtypes in Europe: A collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group.

Authors:  A Lobo; L J Launer; L Fratiglioni; K Andersen; A Di Carlo; M M Breteler; J R Copeland; J F Dartigues; C Jagger; J Martinez-Lage; H Soininen; A Hofman
Journal:  Neurology       Date:  2000       Impact factor: 9.910

6.  Argyrophilic inclusions distinct from Alzheimer neurofibrillary changes in one case of dialysis-associated encephalopathy.

Authors:  E Reusche
Journal:  Acta Neuropathol       Date:  1997-12       Impact factor: 17.088

7.  Patients surviving more than 10 years on haemodialysis. The natural history of the complications of treatment.

Authors:  S A Harris; E A Brown
Journal:  Nephrol Dial Transplant       Date:  1998-05       Impact factor: 5.992

8.  The ICD-10 criteria for vascular dementia.

Authors:  T Wetterling; R D Kanitz; K J Borgis
Journal:  Dementia       Date:  1994 May-Aug

9.  Renal osteodystrophy in asymptomatic hemodialysis patients: evidence of a sex-dependent distribution and predictive value of serum aluminum measurements.

Authors:  D von Herrath; G Asmus; A Pauls; G Delling; K Schaefer
Journal:  Am J Kidney Dis       Date:  1986-12       Impact factor: 8.860

10.  [The natural history of dialysis encephalopathy (author's transl)].

Authors:  H Pogglitsch; O Wawschinek; H Holzer; W Petek; G Ladurner; H Katschnig; C Korthals
Journal:  Acta Med Austriaca       Date:  1980
View more
  9 in total

Review 1.  Human health risk assessment for aluminium, aluminium oxide, and aluminium hydroxide.

Authors:  Daniel Krewski; Robert A Yokel; Evert Nieboer; David Borchelt; Joshua Cohen; Jean Harry; Sam Kacew; Joan Lindsay; Amal M Mahfouz; Virginie Rondeau
Journal:  J Toxicol Environ Health B Crit Rev       Date:  2007       Impact factor: 6.393

Review 2.  Controversies in the Management of Secondary Hyperparathyroidism in Chronic Kidney Disease.

Authors:  Ezequiel Bellorin-Font; George Vasquez-Rios; Kevin J Martin
Journal:  Curr Osteoporos Rep       Date:  2019-10       Impact factor: 5.096

3.  Serum aluminum levels in dialysis patients after sclerotherapy of internal hemorrhoids with aluminum potassium sulfate and tannic acid.

Authors:  Akira Tsunoda; Masafumi Nakagi; Nobuyasu Kano; Masahiko Mizutani; Kenji Yamaguchi
Journal:  Surg Today       Date:  2014-05-11       Impact factor: 2.549

4.  A new paradigm for the treatment of secondary hyperparathyroidism.

Authors:  Angel L M de Francisco; Fernando Carrera
Journal:  NDT Plus       Date:  2008-01

5.  Association between serum aluminum levels and cardiothoracic ratio in patients on chronic hemodialysis.

Authors:  Tzu-Lin Wang; Yu-Wei Fang; Jyh-Gang Leu; Ming-Hsien Tsai
Journal:  PLoS One       Date:  2017-12-20       Impact factor: 3.240

6.  Association of Serum Aluminum Levels with Mortality in Patients on Chronic Hemodialysis.

Authors:  Ming-Hsien Tsai; Yu-Wei Fang; Hung-Hsiang Liou; Jyh-Gang Leu; Bing-Shi Lin
Journal:  Sci Rep       Date:  2018-11-13       Impact factor: 4.379

7.  Acute encephalopathy following the use of aluminum hydroxide in a boy affected with chronic kidney disease.

Authors:  Majid Malaki
Journal:  J Pediatr Neurosci       Date:  2013-01

8.  Association of low serum aluminum level with mortality in hemodialysis patients.

Authors:  Ching-Wei Hsu; Cheng-Hao Weng; Cheng-Chia Lee; Dan-Tzu Lin-Tan; Kuan-Hsing Chen; Tzung-Hai Yen; Wen-Hung Huang
Journal:  Ther Clin Risk Manag       Date:  2016-09-14       Impact factor: 2.423

9.  The Possible Neuroprotective Effect of Silymarin against Aluminum Chloride-Prompted Alzheimer's-Like Disease in Rats.

Authors:  Hanaa R Aboelwafa; Attalla F El-Kott; Eman M Abd-Ella; Hany N Yousef
Journal:  Brain Sci       Date:  2020-09-11
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.